🇺🇸 FDA
Patent

US 10758632

NIR-conjugated tumor-specific antibodies and uses thereof

granted A61KA61K2039/505A61K49/0002

Quick answer

US patent 10758632 (NIR-conjugated tumor-specific antibodies and uses thereof) held by The Regents of the University of California expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/505, A61K49/0002, A61K49/0032, A61K49/0058